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Abstract
Background: Studies on gastrointestinal symptoms, dysfunctions, and neurological disorders in
systemic scleroderma are lacking so far.
Methods: Thirty-eight scleroderma patients (34 limited, 4 diffuse), 60 healthy controls and 68
dyspeptic controls were scored for upper and lower gastrointestinal symptoms (dyspepsia, bowel
habits), gastric and gallbladder emptying to liquid meal (functional ultrasonography) and small bowel
transit (H2-breath test). Autonomic nerve function was assessed by cardiovascular tests.
Results: The score for dyspepsia (mainly gastric fullness) was greater in scleroderma patients than
healthy controls, but lower than dyspeptic controls who had multiple symptoms, instead.
Scleroderma patients with dyspepsia had a longer disease duration. Fasting antral area and
postprandial antral dilatation were smaller in scleroderma patients than dyspeptic and healthy
controls. Gastric emptying was delayed in both scleroderma patients (particularly in those with
abnormal dyspeptic score) and dyspeptic controls, who also showed a larger residual area. Despite
gallbladder fasting and postprandial volumes were comparable across the three groups, gallbladder
refilling appeared delayed in dyspeptic controls and mainly dependent on delayed gastric emptying
in scleroderma. Small intestinal transit was also delayed in 74% of scleroderma and 66% of dyspeptic
controls. Bowel habits were similar among the three groups. Autonomic neuropathy was not
associated with dyspepsia, gastric and gallbladder motility and small intestinal transit.
Conclusion: In scleroderma patients dyspepsia (mainly gastric fullness), restricted distension of
the gastric antrum and diffuse gastrointestinal dysmotility are frequent features. These defects are
independent from the occurrence of autonomic neuropathy.
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Background
Systemic scleroderma (SSc) is a generalized disorder of
small arteries, microvessels and connective tissue of
unknown origin with the highest incidence occurring
between 45 and 55 years of age [1] and with a frequency
of three to eight times higher in females than in males [2].
In SSc different types of antibodies are produced, includ-
ing anti-centromere and anti-topoisomerase antibodies
[3]. Major disease mechanisms are the prominent vascular
changes due to endothelial-cell damage and proliferation
of subendothelial connective tissue. The widespread dam-
age of small arteries and microvessels results in increased
deposition of collagen and other matrix elements, leading
to thickening and fibrosis of the skin, involvement of syn-
ovia and visceral fibrosis [4]. Clinical manifestations of
SSc are extremely heterogeneous and depend on the pres-
ence and degree of internal organ involvement; the two
subsets of SSc include: the Diffuse Cutaneous SSc, charac-
terized by short-term Raynaud's, truncal and acral skin
involvement and significant incidence of interstitial lung
disease, renal failure associated with malignant hyperten-
sion crisis, diffuse gastrointestinal disease, and myocar-
dial involvement; and the Limited Cutaneous SSc,
characterized by Raynaud's for years and limited skin
involvement but significant and late incidence of pulmo-
nary hypertension, with or without interstitial lung dis-
ease, trigeminal neuralgia, skin calcifications,
teleangectasia [4]. Following Raynaud's and skin, the
digestive system is the second most common target of
scleroderma [5], resulting in progressive alterations of
smooth muscle function along the whole gastrointestinal
tract [6-16]. Gastrointestinal involvement in SSc patients
has been linked to several clinical expressions [16] fre-
quently requiring prokinetics drugs, laxatives, proton
pump inhibitors [9] or octreotide [17] but the absence of
evident symptoms is also possible [8] and occurs in about
one third of the patients [13]. Subjects suffering from dif-
ferent connective tissue disorders, including those with
SSc, show a high prevalence rate of autonomic nerve dys-
function and this, in turn, is supposed to affect the gas-
trointestinal motility profile [18-22]. This hypothesis,
however, requires further confirmation. Systematic stud-
ies focusing on gastrointestinal symptoms, dysfunctions,
and neurological alterations in SSc, are lacking so far.
With this in mind and considering the complex and wide
multi-organ involvement in SSc, the present study is
designed to better characterize the profile of gastrointesti-
nal symptoms, motility, and autonomic nervous system
functions in SSc patients, compared to both healthy and
dyspeptic controls.
Methods
Subjects
Patients with SSc were recruited from those referred to the
Rheumatology Department at the University of Bari Med-
ical School. The diagnosis of SSc fulfilled the American
College of Rheumatology (ACR) criteria [4,23] and the
study included 38 consecutive patients (36 females, mean
age 50.9 ± 2.0 years, body mass index of 24.6 ± 0.6 Kg/
m2). According to ACR classification, 34 patients had lim-
ited cutaneous SSc and 4 had diffuse cutaneous SSc. The
estimated duration of the disease was calculated from the
appearance of the first symptom/sign related to SSc and
was 5.8 ± 0.9 years, range 1–21 years. A full range of symp-
toms was carefully investigated for the cardiovascular sys-
tem (dyspnea from pericardial effusion, congestive heart
failure, palpitations and irregular heart beats due to con-
duction abnormalities, and congestive heart failure), skin
(diffuse pruritus, hyper- or hypopigmentation, and skin
tightness and induration), gastrointestinal system (heart-
burn, dysphagia, hoarseness, constipation alternating
with diarrhea, and dyspepsia), respiratory system (dysp-
nea, chest pain from pulmonary artery hypertension, and
cough), musculoskeletal system (arthralgia, myalgia, loss
in joint range of motion, and carpal tunnel syndrome
symptoms), constitutional (fatigue and weight loss), neu-
rological system (facial pain and hand paresthesias from
peripheral entrapment neuropathies, headache, and
stroke), genitourinary system (erectile dysfunction and
dyspareunia), ears, nose, throat, sicca syndrome, and
endocrine system (hypothyroidism). Apart from skin
fibrosis, further clinical features of the patients investi-
gated included: Raynaud's phenomenon (100%), arterial
hypertension (26%), pulmonary interstitial fibrosis (3
out 4 patients and 26% in diffuse cutaneous SSc and lim-
ited cutaneous SSc, respectively), hypertension (2 out 4
patients and 37% in diffuse cutaneous SSc and limited
cutaneous SSc, respectively), and esophageal dysmotility
(95%). All patients underwent gastric endoscopy and
were on antireflux therapy with daily doses of proton
pump inhibitors.
A group of 60 matched healthy volunteers without symp-
toms, medical treatments or a prior history of disease (33
females, mean age 47 ± 2 years, body mass index 23.9 ±
0.5 Kg/m2) served as healthy controls and 68 matched
subjects with no other disease except for functional dys-
pepsia (45 females, mean age 49 ± 2 years, body mass
index 24.9 ± 0.5 Kg/m2) served as dyspeptic controls.
Exclusion criteria for all subjects enrolled in the study
were the presence of gallstones, acute or chronic pancrea-
titis, diabetes, pregnancy, peptic ulcer disease, history of
esophageal and abdominal surgery and any other diseases
or pharmacological treatment (including prokinetics and
calcium channel blockers) known to affect gastrointesti-
nal motility. Exclusion criteria also included the presence
of contraindications for the entire series of cardiovascular
tests, i.e. arrhythmia, recent myocardial infarction, drug
therapy that could interfere with cardiovascular activity,
severe metabolic disturbance and unwillingness to coop-BMC Gastroenterology 2008, 8:7 http://www.biomedcentral.com/1471-230X/8/7
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erate. In addition, subjects were excluded if heavy smokers
(i.e. more than 10 cigarettes/day), alcohol (i.e. more than
20 g ethanol/day in both male and females, respectively)
or drugs abusers. Scleroderma patients who had received
treatment other than small daily doses of steroids, ACE-
inhibitors for arterial hypertension and/or d-penicillanine
were excluded. All patients were evaluated within the
yearly scheduled routine work-up which included blood
tests and abdominal ultrasonography. Approval from the
institutional review board and written informed consent
from the participating subjects were obtained.
Study design
After completing the full work-up at the Rheumatology
Section, SSc patients were asked to join the study on gas-
trointestinal symptoms, motility, and autonomic nervous
system function at the Section of Internal Medicine. All
enrolled subjects underwent complete clinical examina-
tion, an interview by questionnaires for the evaluation of
dyspepsia, upper gastrointestinal perception, and bowel
habits, functional ultrasonography for the study of gall-
bladder and gastric motility, H2-breath test for orocecal
transit time (OCTT). SSc patients also underwent cardio-
vascular tests for autonomic nervous system function (see
below). Tests were started at 08:00 AM. Although the max-
imal length of the work-up was set at 5 hours, the true
length was invariably less than 3 hours.
Dyspepsia and upper gastrointestinal perception
The presence of dyspepsia was assessed and quantified by
a validated semi-quantitative scoring system measuring a
subset of four symptoms (epigastric pain, burning, belch-
ing/burping, postprandial fullness), resulting in a maxi-
mal score equal to 48 [24]. In this series, the upper normal
limit estimated from the mean + 2SDs of healthy controls
was equal to 8 [25,26].
On the day of the motility studies, appetite, satiety, nau-
sea, epigastric fullness and epigastric pain (or discomfort)
were monitored by the visual analogue scale (VAS) [27].
The VAS consisted of a 100 mm-horizontal line indicating
the current intensity of the perception between two
extremes (extreme left = "no symptom at all"; right end =
"maximum feeling of..."). This line was presented to the
subjects who were asked to draw a vertical line through
the horizontal line along its length. The distance in mm
from the extreme left of the line to the vertical line is a
quantitative measure of gastrointestinal perception [28].
Scores at baseline (i.e. time 0) was the mean of 3 measure-
ments over 3 days in the fasting state at the same time in
the morning. Afterwards, VAS was scored at 15, 30, 45, 60,
90 and 120 minutes postprandially. The VAS has been
previously demonstrated as a reliable method to assess
subjective perception in response to experimental stimuli
in the upper gastrointestinal tract [12,27-29].
Bowel habits
The weekly frequency of bowel movements was calculated
from a daily diary over a time span of one month. The
"Bristol" stool form scale was used to assess the quality of
stools based on a semiquantitative scale, as a marker of
colonic transit. The scale is deemed to be a reliable
method to estimate colonic transit time [30,31].
Gastric and gallbladder emptying
Fasting and postprandial course of gastric antral area and
gallbladder volume were assessed by functional ultra-
sonography using a 3.5 MHz convex probe attached to an
Ansaldo-Hitachi equipment, as previously described also
by our group [28,32,33]. The test meal was a 200 mL solu-
tion with 13 g (39%) fat, 10 g (13%) protein and 35 g
(48%) carbohydrates for a total of 300 kcal, 1270 kJ, 365
mOsm/l (Nutridrink®, Nutricia, Milano, Italy). The drink
was taken at room temperature over one minute in the
presence of the examinator. Indices of gastric emptying
were: fasting antral area (mean of 3 measurements at -15,
-5 and 0 minute before test meal, expressed in cm2); max-
imal antral area at 2 minute post-meal; minimal post-
prandial antral area during the 2-hour; half-emptying
time. Gastric emptying curves were obtained by plotting
antral areas vs. time. In order to obviate inter-individual
variability of antrum size [32], postprandial areas were
normalized to maximal area after subtracting basal areas:
i.e. 100 × (At-a)/(A2-a), where At = postprandial area at any
given time; a = basal area; A2 = area at 2 minute postpran-
dially [34]. Half-emptying time was the time at which
50% decrease of antral area occurred (T1/2, minute), and
calculated by linear regression analysis from the linear
descending part of the antral emptying curve. This index
correlates closely with the scintigraphic T1/2 [28]. Gastric
emptying was considered abnormal if T1/2 was greater
than 35 minutes (mean + 2 SD in healthy controls)
[25,26].
Gallbladder emptying was performed simultaneously to
gastric motility by the same operator. Fasting and post-
meal gallbladder volumes were measured by sagittal and
transverse scans of the gallbladder at its largest dimension
at 5–15 minute intervals during 2 hours. Gallbladder vol-
ume was measured from frozen sonograms assuming an
ellipsoid shape of the organ – a reliable method when
gallbladder shape is not highly irregular [35], which was
the case in this study. In healthy subjects the liquid meal
employed in this test (see above) induces more than 50%
emptying of fasting gallbladder volume, and has been val-
idated by our group on several occasions
[25,26,33,36,37]. Indices of gallbladder motility were as
follows: fasting volume (mean of 3 measurements at -15,
-5 and 0 minute before test meal, expressed in mL); resid-
ual volume (minimal volume measured postprandially,
expressed in mL and as percent of fasting volume); T1/2BMC Gastroenterology 2008, 8:7 http://www.biomedcentral.com/1471-230X/8/7
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(time to achieve 50% decrease of fasting volume), calcu-
lated by linear regression analysis from the linear
descending part of the emptying curve [36]. Gallbladder
emptying was considered abnormal if half-emptying time
was greater than 35 minutes (mean + 2 SD in healthy con-
trols) [25,26].
Orocecal transit time (OCTT)
OCTT was measured by the hydrogen (H2) breath test
[38]. During the 5 days before the test, subjects were not
allowed to take antibiotics, probiotics, prokinetics or
other drugs known to affect gastrointestinal motility. To
avoid prolonged intestinal H2-production secondary to
the presence of non-absorbable or slowly fermentable
material in the colonic lumen, a special diet was given
starting the day before the test and consisting of proteins
and fat (meat, fish, eggs, olive oil) [25,26,39]. The meal
was followed by a 12-hour fasting period. Between 08:00
and 09:00 AM the test was started. Smoking and physical
exercise were prohibited one hour before and during the
test [40,41]. Two breath samples were taken in the fasting
state and afterwards the subject ingested 10 g of lactulose
(Duphalac Dry®, Solvay Pharma, Torino, Italy) added
directly as a powder to the liquid test meal used for simul-
taneous study of gallbladder and gastric emptying. End-
respiratory breath samples were analyzed every 10 min-
utes for five hours after lactulose ingestion, using a pre-
calibrated, portable hydrogen sensitive electrochemical
devices (EC60-Gastrolyzer, Bedfont, USA and Lactofan H2
Analyzer, Fisher Analysen Instr. Leipzig, Germany, kindly
donated by Italchimici SpA, Pomezia, Rome, Italy). The
concentration of hydrogen was measured in parts per mil-
lion (ppm), and the accuracy of the detector was ± 2 ppm.
A rise of 10 ppm above baseline on two consecutive meas-
urements was considered as OCTT and expressed in
minute [38]. In all subjects a hydrogen peak was evident,
thus excluding the presence of non-H2 producers. OCTT
was considered delayed if greater than 120 minutes (i.e.
the mean+2SD obtained by a large healthy control group)
[25,26]. The presence of small intestinal bacterial over-
growth was excluded by H2 breath test as previously vali-
dated [42] and according to published criteria [43]. The
lactulose breath test was considered normal if there was
no rise in H2 concentration during the first 90 minutes
after lactulose ingestion, with a definitive rise never
greater than 20 ppm during 180 minutes of measurement
[44].
Autonomic neuropathy
The integrity of the autonomic nervous system was
assessed by both the Sweat-Spot-Test (SST) [38,45,46] and
cardiorespiratory reflex tests [47], as previously described
by our group [26]. The SST was used to investigate the
presence of cholinergic sympathetic fibers alterations by
analyzing sweat abnormalities on the skin of the dorsum
of the foot, which was coated with iodine and a fine emul-
sion of starch in arachis oil. Sweat was stimulated either
by an intra-dermal injection of 0.1 mL acetylcholine
(Ach.SST), or a standardized thermal stimulus which
includes pre-ganglionic fibers (Thermal SST). A colorimet-
ric reaction between starch and iodine was triggered by the
sweat from stimulated glands, so that each pore was seen
as a little black dot after 2–5 minutes. A digital photo was
obtained and transferred to a magnifying software to
measure the number and distribution of dots appearing in
a standard squared grid of 529 mm2 divided into 64
squared subareas. A normal SST was expressed by a score
≥ 12 dots/subarea and/or < 8% of abnormal subareas
(each square of the grid having less than 6 dots), accord-
ing to Ryder [45] and to our group [26,46]. Only patients
with both indices (SST score and % of abnormal subareas)
outside normal limits were considered to have a positive
test. A portable device (Cardionomic®, Lifescan, Italy) con-
nected to skin electrodes was employed to measure the
"beat-to-beat" modifications of the R-R interval. Lying-to-
standing and standing-to-lying tests were used to assess
sympathetic involvement. Valsalva maneuver, deep-
breathing, cough test, and postural hypotension test were
used for parasympathetic involvement. The results from
each test were scored as normal, borderline or abnormal,
according to age-controlled values. The overall results for
autonomic neuropathy were therefore normal (all tests
normal), early involvement (one abnormal test or two
borderline abnormal), definitive involvement (two or
more abnormal tests) [26,48].
Data analysis
Calculations were performed with the NCSS 2007 statisti-
cal software (Hintze J, 2006, Kaysville, UT, USA), and data
expressed as the mean ± standard error (SE). Continuous
variables were analyzed using ANOVA  followed by
Fisher's LSD test. Differences between two subgroups were
evaluated by Mann-Whitney U-test or by Student's t test,
where appropriate. Linear regression analysis was per-
formed by the method of least square. The chi-square test
was used to compare categorical variables and propor-
tions. A two-tailed probability (P) value of less than 0.05
was considered statistically significant [49,50].
Results
Symptoms
The score for dyspepsia was abnormal in 61% of SSc
patients, with a mean score greater than healthy controls,
but lower than dyspeptic controls (Table 1). This was also
seen when dyspeptic controls were compared with sclero-
derma patients with abnormal dyspeptic score (n = 23,
mean score 17.3 ± 1.5, P = 0.0009). Estimated disease
duration was significantly (P = 0.03) longer in SSc patients
with abnormal dyspepsia score (7.3 ± 1.4 years) than in
those without dyspepsia (3.4 ± 0.6 years).BMC Gastroenterology 2008, 8:7 http://www.biomedcentral.com/1471-230X/8/7
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The analysis of dyspeptic symptoms by VAS throughout
the motility study showed that the feeling of appetite and
satiety were similar in SSc patients, healthy and dyspeptic
controls. As expected, the perception of satiety and appe-
tite (either in fasting and postprandial period) showed a
strong negative correlation in both patients and controls
(r = -0.80; P = 0.000001).
Dyspeptic controls had more nausea than both SSc
patients and healthy controls (Table 1).
Of note, perception of epigastric fullness in SSc patients
was constantly higher than in healthy controls, although
dyspeptic controls had the highest score for this symptom
(Table 1 and Figure 1). Finally, dyspeptic controls showed
higher perception of epigastric pain than both SSc
patients and healthy controls (Table 1).
Despite the low number of patients with diffuse SSc
enrolled in the present study, no difference was evident
between patients with limited or diffuse scleroderma for
either dyspepsia score (12.8 ± 1.5 and 11.0 ± 2.3, respec-
tively, P = NS) or dyspeptic symptoms by VAS (data not
shown).
Functional studies
Gastric emptying
SSc patients had a significantly smaller antral area in the
fasting state and a minor postprandial dilatation of the
gastric antrum than both dyspeptic and healthy controls
(Table 2). During most of the postprandial period
(between 10 and 120 minutes), both SSc patients and dys-
peptic controls had significantly larger antral areas than
healthy controls (Figure 2). Furthermore, dyspeptic con-
trols showed the mostly impaired gastric emptying, since
they also had higher postprandial areas than SSc patients
between 40 and 120 minutes (Figure 2). Consequently,
this resulted in a larger minimal postprandial antral area
and in a delayed T1/2 in both SSc patients and dyspeptic
controls, compared to those in healthy controls (Table 2).
Dyspeptic controls also showed a larger minimal post-
prandial antral area compared to SSc patients (Table 2).
Overall, postprandial gastric emptying was abnormal in
50% of SSc patients and in 59% of dyspeptic controls. A
delayed postprandial gastric emptying was found in
65.2% of scleroderma patients with an abnormal dyspep-
tic score. Among SSc patients, emptying time was particu-
larly delayed in patients with abnormal dyspeptic score,
compared to those without dyspepsia (T1/2: 49 ± 9 min-
utes and 33 ± 3 minutes, respectively, P = 0.04). No differ-
Time-course of Visual Analogue Scale (VAS) for epigastric  fullness in the fasting state (Time 0) and at regular intervals  postprandially during the motility tests in SSc patients (white  circles), healthy controls (black circles) and in dyspeptic con- trols (white squares) at each time point Figure 1
Time-course of Visual Analogue Scale (VAS) for epi-
gastric fullness in the fasting state (Time 0) and at 
regular intervals postprandially during the motility 
tests in SSc patients (white circles), healthy controls 
(black circles) and in dyspeptic controls (white 
squares) at each time point. Vertical lines indicate SE val-
ues. In the inset: Area Under Curve *P < 0.01 vs healthy con-
trols; °P < 0.01 vs both SSc patients and healthy controls 
(ANOVA followed by Fisher's LSD test).
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Table 1: Dyspepsia score and Visual Analogue Scale of five major dyspeptic symptoms in scleroderma (SSc) patients and in dyspeptic 
and healthy controls
SSc patients Dyspeptic controls Healthy controls P (ANOVA)
Dyspepsia score 12.4 ± 1.01 23.7 ± 0.81,2 5.4 ± 0.8 0.000001
Appetite 397.8 ± 43.9 258.8 ± 33.53 313.6 ± 34.0 NS
Satiety 784.0 ± 40.0 828.5 ± 30.4 772.9 ± 31.0 NS
Nausea 18.6 ± 25.7 131.9 ± 19.71,2 11.0 ± 20.0 0.00003
Epigastric fullness 119.5 ± 36.01 363.0 ± 27.41,2 15.7 ± 27.8 0.000001
Epigastric pain 34.0 ± 26.0 136.2 ± 19.91,2 2.0 ± 20.2 0.00001
Data are expressed as means ± SE of Area Under Curve from 0 (fasting) to 120 minutes postprandially. Differences among groups were tested by 
Fisher's LSD Multiple Comparison test.
1P < 0.05 vs controls; 2P < 0.05 vs SSc patients.BMC Gastroenterology 2008, 8:7 http://www.biomedcentral.com/1471-230X/8/7
Page 6 of 11
(page number not for citation purposes)
ence was evident between patients with limited or diffuse
scleroderma as far as fasting antral areas and postprandial
antral emptying were concerned (data non shown).
Gallbladder emptying
There was no difference in SSc patients vs dyspeptic and
healthy controls for fasting volume and postprandial indi-
ces of gallbladder emptying (Table 2). Although the post-
prandial gallbladder emptying profile was fully
comparable in SSc patients vs. both dyspeptic and healthy
controls, gallbladder refilling was impaired in SSc patients
and dyspeptic controls, compared to healthy controls
(Figure 2).
In order to assess the influence of gastric emptying on gall-
bladder dynamics, the postprandial gallbladder motility
in subjects with normal or abnormal gastric emptying was
also compared in SSc patients and dyspeptic controls.
Interestingly, although the gallbladder emptying was sim-
ilar in subjects with or without altered gastric emptying,
an altered gallbladder refilling was only found in SSc
patients with delayed gastric emptying. This was not the
case, however, of dyspeptic controls, who showed similar
gallbladder emptying and refilling curves accompanied
with normal or impaired gastric emptying (Figure 3). No
difference was evident in patients with limited or diffuse
scleroderma as far as fasting and postprandial gallbladder
volumes were measured (data not shown).
Orocecal transit time (OCTT)
Fasting levels of H2 were invariably less than 10 ppm in all
subjects and did not differ between patients and controls.
None of the subjects showed evidence of small bowel bac-
terial overgrowth. However, OCTT was significantly
longer in both SSc patients and dyspeptic controls com-
pared to healthy controls, with values being above the
upper normal limit as detected in 74% of SSc patients and
in 66% of dyspeptic controls (Table 2). OCTT was pro-
longed in 69.5% of SSc patients with an abnormal dys-
peptic score. No difference in OCTT was found in subjects
with or without an altered gastric emptying in both SSc
patients (171.2 ± 12.2 and 173.3 ± 13.2, respectively; P =
NS) and dyspeptic controls (164.6 ± 10.1 and 148.9 ± 8.9,
respectively; P = NS). No difference was evident in
patients with limited (178.4 ± 9.4 min) or diffuse sclero-
derma (147.5 ± 25.0 min, P = NS) as far as orocecal transit
time was concerned.
Bowel habits
There was no difference in SSc patients vs dyspeptic and
healthy controls when both weekly frequency of evacua-
tions (5.2 ± 1.5, 5.4 ± 1.6 and 5.9 ± 2.0 respectively, P =
NS) and bowel habits were investigated by Bristol score
(3.4 ± 0.2, 3.8 ± 0.2 and 3.6 ± 0.1 respectively, P = NS). No
difference was observed in patients with limited or diffuse
scleroderma as far as bowel habits was examined (Bristol
score 3.4 ± 0.3 and 3.6 ± 0.7, respectively, P = NS).
Autonomic neuropathy
Twenty-nine out of 38 patients and all of controls gave
their informed consent to undergo tests for autonomic
neuropathy. In terms of clinical features, this subgroup
was fully representative of the whole SSc group of patients
(n = 25 with limited and n = 4 with diffuse disease). Over-
all, tests for autonomic neuropathy were abnormal in 20
(69%) of the patients but in none of the controls. Abnor-
mal parasympathetic function, sympathetic function or
both were found in 79%, 55% and 41% of cases, respec-
Table 2: Gastrointestinal motility indices in scleroderma (SSc) patients and in dyspeptic and healthy controls
SSc patients Dyspeptic controls Healthy controls P (ANOVA)
Stomach
Fasting antral area (cm2) 2.9 ± 0.11 3.4 ± 0.12 3.5 ± 0.1 0.004
Maximal postprandial area (cm2)1 0 . 7  ±  0 . 3 1 11.8 ± 0.22 12.3 ± 0.2 0.0002
Minimal postprandial area (%) 8.3 ± 2.01 15.6 ± 1.51,2  2.0 ± 1.8 0.000001
Half-emptying time (minute) 42 ± 41 47 ± 31 26 ± 3 0.000001
Abnormal emptying (%) 501 571 3 0.0001
Gallbladder
Fasting volume (mL) 25.2 ± 1.5 24.8 ± 1.0 22.0 ± 1.1 NS
Postprandial residual volume (%) 26.8 ± 2.5 28.0 ± 1.5 26.5 ± 1.5 NS
Postprandial residual volume (mL) 6.6 ± 0.9 7.0 ± 0.6 5.9 ± 0.6 NS
Half-emptying time (minute) 25.1 ± 2.3 25.4 ± 1.2 22.1 ± 1.3 NS
Abnormal emptying (%) 0 0 0 NS
Small bowel
Orocecal transit time* (minute) 172.3 ± 7.41 158.0 ± 5.51 98.7 ± 5.5 0.000001
Abnormal transit (%) 741 661 11 0.0001
Results are expressed as means ± SE. Differences among groups were tested by Fisher's LSD Multiple Comparison test. The chi-square test was 
used to compare proportions. NS = no significant difference; 1P < 0.05 vs controls; 2P < 0.05 vs SSc. *not done in 3 SSc patients and in 3 dyspeptic 
patients.BMC Gastroenterology 2008, 8:7 http://www.biomedcentral.com/1471-230X/8/7
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tively. According to disease classification, tests for auto-
nomic neuropathy were abnormal in 15 out of 25 patients
(60%) with limited disease and in 1 out of 4 subjects
(25%) with diffuse scleroderma. No significant differ-
ences could be detected in patients with respectively nor-
mal or abnormal tests for dyspeptic scores (13.0 ± 3.3 and
11.6 ± 1.7,), bowel habits (Bristol score 3.7 ± 0.6 and 3.4
± 0.3), fasting gallbladder volume (22.5 ± 2.3 and 25.2 ±
2.1 mL), residual gallbladder volume (6.4 ± 1.8 and 5.7 ±
0.7 mL), fasting postprandial antral areas (2.8 ± 0.1 and
2.9 ± 0.2 cm2), postprandial antral areas (3.4 ± 2.1 and 5.1
± 1.4%), antral half-emptying time (36.7 ± 4.4 and 34.3 ±
2.4 min), and OCTT (190.0 ± 16.0 and 158.3 ± 11.3 min-
utes).
Discussion
Systemic scleroderma is a rare disorder with an annual
incidence of 19.3 cases per million adults in the United
States. Renal and pulmonary diseases are the major causes
of mortality. Survival has improved over the past few dec-
ades and is strongly dependent on the degree of organ
Top panel Time-course of gallbladder volume in SSc patients  with normal (black circles, N = 18) or abnormal (white cir- cles, N = 17) gastric emptying, after ingestion of the standard  liquid meal Figure 3
Top panelTime-course of gallbladder volume in SSc 
patients with normal (black circles, N = 18) or abnor-
mal (white circles, N = 17) gastric emptying, after 
ingestion of the standard liquid meal. *P < 0.05 vs 
patients with abnormal gastric emptying (Mann-
Whitney U-test). Bottom panel: Time-course of gallblad-
der volume in dyspeptic controls with normal (black squares, 
N = 29) or abnormal (white squares, N = 39) gastric empty-
ing, after ingestion of the standard liquid meal. P = NS at each 
time point (Mann-Whitney U-test).
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SSc patients
Time-course of percentage antral area as index of gastric  emptying (top panel) and of gallbladder volume (bottom  panel) in SSc patients (white circles), healthy controls (black  circles) and in dyspeptic controls (white squares) after inges- tion of the standard liquid meal Figure 2
Time-course of percentage antral area as index of 
gastric emptying (top panel) and of gallbladder vol-
ume (bottom panel) in SSc patients (white circles), 
healthy controls (black circles) and in dyspeptic con-
trols (white squares) after ingestion of the standard 
liquid meal. Symbols indicate mean values while vertical 
lines indicate SE values at each time-point. Top panel (gastric 
emptying): *P < 0.01 SSc patients and dyspeptic controls vs 
healthy controls from time 10 minutes to time 120 minutes, 
and SSc patients vs dyspeptic controls from time 40 minutes 
to time 120 minutes (ANOVA followed by Fisher's LSD test). 
Bottom panel (gallbladder emptying): *P < 0.05 dyspeptic vs 
healthy controls from time 60 minutes to time 120 minutes, 
and SSc patients vs healthy controls from time 90 minutes to 
time 120 minutes (ANOVA followed by Fisher's LSD test).
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involvement. Gastrointestinal involvement is common in
both forms of limited and diffuse SSc. Indeed, in this
series, esophageal dysmotility and complaints such as
heartburn and various degrees of dysphagia are exten-
sively represented and need medication with antisecretory
and/or prokinetic agents.
Despite gastrointestinal symptoms [8,12,13,16,29],
motility dysfunctions [6-16] and autonomic neuropathy
[18-22] have been very often associated with SSc, compre-
hensive studies on this topic were not available, so far.
This is the first study providing an integrated overview of
gastrointestinal manifestations, autonomic neuropathy
and motility disorders in SSc patients and taking a group
of functional dyspepsia patients as additional controls.
Several observations demonstrated that a symptomatic
[16] or an asymptomatic [8] involvement of the gastroin-
testinal tract was the second most common manifestation
of scleroderma [5] and that gastrointestinal motility dys-
function remains subclinical in about one third of SSc
patients [13]. Our data confirm and expand such early
reports and we show here that about one half of SSc
patients (particularly after a longlasting disease) develop
gastrointestinal symptoms (apart from esophageal heart-
burn and dysphagia), although their intensity is less
important than that of subjects with functional dyspepsia.
Epigastric fullness was the main dyspeptic symptom
recorded in our series of SSc patients both in the fasting
state and throughout the postprandial period, and this is
at variance with dyspeptic controls, who showed similar
frequency of multiple symptoms. Of note, by integrating
the analysis of this symptom with ultrasonographic gas-
tric motility, we show here that about 35% of scleroderma
patients had an abnormal dyspeptic score with a normal
postprandial gastric emptying speed. Thus, a small and
stiff antral area, might mainly account for epigastric full-
ness in SSc patients, rather than a delayed gastric empty-
ing "per se". This finding, together with a restricted
distension of the gastric antrum in SSc patients following
200 mL test meal, distinguish these patients from subjects
with functional dyspepsia, who show both a basal area
and a gastric distention capacity similar to those of
healthy controls.
Although an histological examination of the stomach to
check for the degree of fibrosis was not performed here,
the hypothesis of a stiff gastric wall, with an altered
smooth muscle basal tone, might be supported by previ-
ous observations demonstrating a prominent fibrosis [51]
and features of atrophy of muscle layers, with wide areas
of focal fibrosis surrounding smooth muscle cells [52] in
gastric wall of SSc patients. Furthermore, similar to the
suggested alterations for the duodenal wall [12], an
increased sensitivity of receptors-mediated perception in
SSc patients compared to healthy subjects cannot be ruled
out. In SSc patients, in fact, a stiffer duodenal wall and an
increased sensation of pain evoked by a controlled strain
of the gut has been previously demonstrated [12].
A defective gastric emptying has been frequently reported
in subjects with functional dyspepsia [53]. In the post-
prandial period our data show the existence of an altered
gastric smooth muscle function in both SSc patients and
subjects with functional dyspepsia, thus confirming previ-
ous observations by ultrasonography and other diagnostic
techniques [7,8,10,15,16,54-59]. Our results suggest that
deranged gastric emptying is associated with the presence
of symptoms, as it is particularly evident in both subjects
with functional dyspepsia and SSc patients with abnormal
dyspeptic score. Although in this latter group the anatom-
ical damage of the gastrointestinal smooth muscle is not
necessarily dependent on the duration of the disease, the
functional alteration might be, at least in part, related to
it. This last hypothesis is supported by a previous ultra-
sonographic study, demonstrating a significant correla-
tion between a delayed gastric emptying and the duration
of scleroderma [59].
We show that OCTT is delayed in both SSc patients and
dyspeptic controls, irrespective of an altered gastric emp-
tying. In fact, OCTT was similar in subjects with or with-
out altered gastric emptying in both SSc patients and
dyspeptic controls, suggesting that this factor plays a lim-
ited role in the determination of a delayed OCTT, at least
in the present series. Orocecal transit time appears to be
altered to a similar extent in both SSc patients and dyspep-
tic controls with normal gastric emptying. Thus, small
bowel-related and gastric motility-independent factors
including increased stiffness of small bowel wall with
altered muscle function [12,16,60], altered motilin levels
[61] and/or an "acidic stress" with sensorimotor disorders
[62,63] are likely involved in this dysfunction.
In SSc patients the percentage of the subjects with a
delayed OCTT is doubled compared to that of another
study employing the same technique [15]. Differences in
patients selection and stage of the disease might probably
explain such discrepancies. Of note, small intestinal bac-
terial overgrowth was absent in our subjects, meaning
either careful clinical and therapeutic control or a pre-
served colonic function (see below).
Previous studies demonstrated the presence of an altered
colonic smooth muscle function [6] and delayed colonic
transit with constipation in SSc patients [14,15,64]. How-
ever, we could not confirm these findings by using specific
visual-semiquantitative scales (the Bristol Stool Form
Scale is deemed to be a reliable method to estimateBMC Gastroenterology 2008, 8:7 http://www.biomedcentral.com/1471-230X/8/7
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colonic transit time [30]). Thus, it appears that the group
of patients investigated here has a rather preserved colonic
function, despite a delayed small bowel transit that might
partly account for the abnormal orocecal transit time.
Since colonic function is frequently abnormal in diffuse
SSc [65], the high proportion of patients with limited SSc
in our series (34 of 38 patients) might partly account for
this discrepancy.
As far as gallbladder motility is concerned, there are con-
flicting and inconclusive results from previous observa-
tions in gallstone-free patients with dysmotility-like
dyspepsia [66]. At variance from the motility data of the
stomach, the present study corroborates previous observa-
tions indicating a normal gallbladder fasting volume and
emptying pattern in SSc patients [59,67-69]. The fact that
the gallbladder emptying is unaffected suggests that the
physiological entero-hormonal and neurological path-
ways governing the upper gastrointestinal motility play a
minor role in the genesis of functional disturbances in
scleroderma. It is therefore likely that anatomically altered
muscular layer of gastrointestinal organs [6,9,51,52,70],
rather than extrinsic factors, are responsible for the
smooth muscle dysfunction.
However, at variance with the gallbladder emptying, the
gallbladder refilling has been shown to be altered in both
SSc patients and dyspeptic controls. In SSc patients this
finding appears to be related to the delayed gastric empty-
ing rather than to a neuro-muscular dysfunction. At least
in our series, however, this was not the case of dyspeptic
controls, who showed an altered gallbladder refilling irre-
spective of gastric emptying speed.
Interestingly, it has been recently suggested that a long
term treatment with octreotide LAR may be effective for
treatment of small intestinal disease in SSc patients [17].
However, also taking into account the altered gallbladder
refilling noticed in SSc patients, this therapeutic option
should be considered with caution, since the long-acting
octreotide formulation has been shown to greatly increase
the risk of gallstone formation probably by suppression of
endogenous cholecystokinin release [71].
Autonomic nerve dysfunction has been found in patients
with SSc [18-22]. However, for the first time in SSc, we
could add the Sweat Spot test to other standard cardiovas-
cular tests for assessing autonomic denervation. Deranged
function of the autonomic nervous system, similar to that
observed in other conditions (i.e. diabetes mellitus), has
been suggested for explaining the functional defects in SSc
patients [18-22,54,72,73]. The integrated approach used
in this study show that, although autonomic neuropathy
is very frequent in SSc patients, it seems to have no role in
generating gastrointestinal motility disorder, since both
symptoms characteristics and motility patterns at multi-
ple levels are similar in patients with or without abnormal
parasympathetic and/or sympathetic function. However,
the pathogenesis of gastrointestinal dysmotility in SSc
patients might be secondary to an independent ischemic
process to local nerves rather than on a systemic auto-
nomic dysfunction [5,54,74,75]. In particular, early vas-
cular lesions might induce initial axonal degeneration,
followed by subsequent focal degeneration of the smooth
muscle cells [21].
The correlation between gastrointestinal dysfunction and
symptoms in SSc patients appears to be closer in our,
rather than in other studies [8,16,75]. Probably, differ-
ences in patients selection, in study design and in the
employed techniques might explain this partial discrep-
ancy.
Conclusion
In conclusion, the present study shows that SSc patients
frequently suffer from dyspepsia independently from
autonomic neuropathy, and that dyspeptic symptoms are
associated with gastrointestinal dysmotility. At variance
with functional dyspepsia, SSc patients principally com-
plain of epigastric fullness and show a restricted disten-
sion of the gastric antrum. Similarly to dyspeptic subjects,
exhibit multiple gastrointestinal motility defects, in which
fibrosis and anatomical alterations might play a major
causative role, rather than a simple neuro-muscular dys-
function.
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